Literature DB >> 27699719

177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.

Kambiz Rahbar1, Martin Bögemann2, Hojjat Ahmadzadehfar3.   

Abstract

Entities:  

Keywords:  PSMA-617; Radioligand therapy; mCRPC

Mesh：

Substances：

Year:  2016        PMID： 27699719     DOI： 10.1007/s00259-016-3530-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.

Authors:  Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar
Journal:  J Nucl Med       Date:  2016-04-07       Impact factor: 10.057

2.  177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.

Authors:  Madhav Prasad Yadav; Sanjana Ballal; Madhavi Tripathi; Nishikant Avinash Damle; Ranjit Kumar Sahoo; Amlesh Seth; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-10       Impact factor: 9.236

3.  Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.

Authors:  Kambiz Rahbar; Axel Bode; Matthias Weckesser; Nemanja Avramovic; Michael Claesener; Lars Stegger; Martin Bögemann
Journal:  Clin Nucl Med       Date:  2016-07       Impact factor: 7.794

4.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Authors:  Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2016-03-16       Impact factor: 10.057

Review 5.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

6.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

7.  Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy.

Authors:  Constantin Lapa; Rudolf A Werner; Christina Bluemel; Katharina Lueckerath; Dirk O Muegge; Alexander Strate; Heribert Haenscheid; Andreas Schirbel; Martin S Allen-Auerbach; Ralph A Bundschuh; Andreas K Buck; Ken Herrmann
Journal:  EJNMMI Res       Date:  2014-12-24       Impact factor: 3.138

8.  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler
Journal:  EJNMMI Res       Date:  2015-06-20       Impact factor: 3.138

9.  Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

Authors:  Hojjat Ahmadzadehfar; Elisabeth Eppard; Stefan Kürpig; Rolf Fimmers; Anna Yordanova; Carl Diedrich Schlenkhoff; Florian Gärtner; Sebastian Rogenhofer; Markus Essler
Journal:  Oncotarget       Date:  2016-03-15
  9 in total
  5 in total

Review 1.  Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

Authors:  Zool Hilmi Awang; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Radiat Oncol       Date:  2018-05-23       Impact factor: 3.481

2.  Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Authors:  Ali Afshar-Oromieh; Nils Debus; Monika Uhrig; Thomas A Hope; Michael J Evans; Tim Holland-Letz; Frederik L Giesel; Klaus Kopka; Boris Hadaschik; Clemens Kratochwil; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-07       Impact factor: 9.236

3.  Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT.

Authors:  Guiyang Hao; Tara Mastren; William Silvers; Gedaa Hassan; Orhan K Öz; Xiankai Sun
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

4.  Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.

Authors:  Song Xue; Andrei Gafita; Chao Dong; Yu Zhao; Giles Tetteh; Bjoern H Menze; Sibylle Ziegler; Wolfgang Weber; Ali Afshar-Oromieh; Axel Rominger; Matthias Eiber; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-30       Impact factor: 10.057

5.  Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.

Authors:  Ali Afshar-Oromieh; Uwe Haberkorn; Christian Zechmann; Thomas Armor; Walter Mier; Fabian Spohn; Nils Debus; Tim Holland-Letz; John Babich; Clemens Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-09       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.